204 related articles for article (PubMed ID: 34586531)
21. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma.
Kinami T; Uchikawa S; Kawaoka T; Yamasaki S; Kosaka M; Johira Y; Yano S; Amioka K; Naruto K; Yamaoka K; Fujii Y; Fujino H; Nakahara T; Ono A; Murakami E; Okamoto W; Yamauchi M; Miki D; Tsuge M; Oka S
Cancer Med; 2024 Mar; 13(5):e7025. PubMed ID: 38477514
[TBL] [Abstract][Full Text] [Related]
22. Cure can be Achieved by Conversion to Microwave Ablation following Atezolizumab-Bevacizumab Therapy in Unresectable Hepatocellular Carcinoma.
Febro RJD; Perillo ESS; Kimura AA; Wong SN
J Liver Cancer; 2024 Jun; ():. PubMed ID: 38825875
[TBL] [Abstract][Full Text] [Related]
23. Atezolizumab plus bevacizumab as a downstaging therapy for liver transplantation in hepatocellular carcinoma with portal vein thrombosis: The first report.
Kumar P; Krishna P; Nidoni R; Adarsh CK; Arun MG; Shetty A; Mathangi J; Sandhya ; Gopasetty M; Venugopal B
Am J Transplant; 2024 Jun; 24(6):1087-1090. PubMed ID: 38219868
[TBL] [Abstract][Full Text] [Related]
24. [Our Experience with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma].
Shimizu J; Yamashita M; Odagiri K; Takeyama H; Yanagimoto Y; Suzuki Y; Ikenaga M; Kawase T; Imamura H; Dono K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1513-1515. PubMed ID: 38303325
[TBL] [Abstract][Full Text] [Related]
25. Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma.
Villalobos A; Dabbous HH; Little O; Gbolahan OB; Akce M; Lilly MA; Bercu Z; Kokabi N
Curr Oncol; 2023 Nov; 30(12):10100-10110. PubMed ID: 38132368
[TBL] [Abstract][Full Text] [Related]
26. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Hack SP; Spahn J; Chen M; Cheng AL; Kaseb A; Kudo M; Lee HC; Yopp A; Chow P; Qin S
Future Oncol; 2020 May; 16(15):975-989. PubMed ID: 32352320
[TBL] [Abstract][Full Text] [Related]
27. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
Ando Y; Kawaoka T; Kosaka M; Shirane Y; Johira Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Kosaka Y; Uchikawa S; Kodama K; Fujino H; Nakahara T; Ono A; Murakami E; Yamauchi M; Okamoto W; Takahashi S; Imamura M; Chayama K; Aikata H
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439111
[TBL] [Abstract][Full Text] [Related]
28. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Nakabori T; Higashi S; Abe Y; Mukai K; Ikawa T; Konishi K; Maeda N; Nakanishi K; Hasegawa S; Wada H; Ohkawa K
Curr Oncol; 2024 Mar; 31(3):1543-1555. PubMed ID: 38534950
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hepatocellular carcinoma with a portal vein tumor thrombus and pulmonary metastases of rectal cancer with microsatellite stability using atezolizumab plus bevacizumab.
Inaba Y; Chatani S; Murata S; Sato Y; Imamine R; Kato M; Onaya H; Yamaura H
Clin J Gastroenterol; 2024 Apr; 17(2):286-291. PubMed ID: 38341819
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.
Brown TJ; Mamtani R; Gimotty PA; Karasic TB; Yang YX
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2345-2354. PubMed ID: 36862158
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Yano S; Kawaoka T; Yamasaki S; Johira Y; Kosaka M; Shirane Y; Miura R; Amioka K; Naruto K; Yamaoka K; Fujii Y; Uchikawa S; Fujino H; Ono A; Nakahara T; Murakami E; Miki D; Tsuge M; Teraoka Y; Kouno H; Takaki S; Mori N; Tsuji K; Oka S
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001666
[TBL] [Abstract][Full Text] [Related]
32. Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports.
Yeom KM; Song YG; Yoo JJ; Kim SG; Kim YS
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256417
[No Abstract] [Full Text] [Related]
33. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract][Full Text] [Related]
34. Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.
Campani C; Vallot A; Ghannouchi H; Allaire M; Evain M; Sultanik P; Sidali S; Blaise L; Thabut D; Nahon P; Seror O; Ganne-Carrié N; Nault JC; Wagner M; Sutter O
Hepatology; 2024 Jan; 79(1):49-60. PubMed ID: 37870270
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.
Joerg V; Scheiner B; D Alessio A; Fulgenzi CAM; Schönlein M; Kocheise L; Lohse AW; Huber S; Wege H; Kaseb A; Wang Y; Mathew A; Kuang A; Muzaffar M; Abugabal YI; Chamseddine S; Phen S; Cheon J; Lee PC; Balcar L; Krall A; Ang C; Wu L; Saeed A; Huang YH; Bengsch B; Rimassa L; Weinmann A; Stauber R; Korolewicz J; Pinter M; Singal AG; Chon HJ; Pinato DJ; Schulze K; von Felden J
Hepatol Commun; 2023 Nov; 7(11):. PubMed ID: 37889520
[TBL] [Abstract][Full Text] [Related]
36. Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
Kobayashi S; Fukushima T; Ueno M; Chuma M; Numata K; Tsuruya K; Arase Y; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Uojima H; Hidaka H; Kusano C; Morimoto M; Maeda S
Liver Int; 2024 Jun; 44(6):1343-1350. PubMed ID: 38436529
[TBL] [Abstract][Full Text] [Related]
37. Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration.
Alkadimi MA; Aldawoodi TA; Lucero KT; Fierro ME; Boyle LD; Mader MJ; Franklin KR; Arora SP; Nooruddin Z
Oncologist; 2024 May; 29(5):369-376. PubMed ID: 38254242
[TBL] [Abstract][Full Text] [Related]
38. A combination of locoregional treatment with systemic therapy after atezolizumab plus bevacizumab failure for unresectable hepatocellular carcinoma provides survival benefit.
Su CW; Teng W; Lin PT; Wu TH; Hsu YC; Hsieh YC; Huang CH; Chen WT; Lin CC; Lin CY; Lin SM
Am J Cancer Res; 2023; 13(11):5482-5492. PubMed ID: 38058809
[TBL] [Abstract][Full Text] [Related]
39. [Significance of neutrophil-to-lymphocyte ratio in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma].
Kaneko Y; Kaneshiro M; Watanabe H
Nihon Shokakibyo Gakkai Zasshi; 2023; 120(10):837-844. PubMed ID: 37821373
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography.
Uchikawa S; Kawaoka T; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Miki D; Imamura M; Aikata H
J Med Ultrason (2001); 2023 Jan; 50(1):57-62. PubMed ID: 36169740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
